Product information and disease descriptionProduct description
Phase of product development
22 evidence topics · 15 sources
Regulatory status: Submission planned; NDA submission planned for 2027
Launch: Anticipated in 2028
OPERA-01 top-line data expected in the first quarter of 2027 (November 2026)
OPERA-01 enrollment completed and top-line timing moved to the first quarter of 2027 (August 2026)
Earlier guidance: top-line data in fall 2026 and launch in 2027 (May 2026)
Earlier guidance: top-line data in fall 2026, NDA in 2027, and approval and launch in late 2027 (March 2026)
Earlier guidance: top-line data in the second half of 2026 (August 2025)
Earlier guidance: top-line data in 2026 and launch in 2027 (May 2025)
Earlier guidance: top-line data in 2026 (December 2024)
Fast Track designation, July 2022
Fast Track designation: eligibility for priority review, accelerated approval, and rolling submission
Dose of 90 mg once daily selected in alignment with FDA, May 2025
OPERA-01: first participant dosed in November 2023
OPERA-02: initiated in the third quarter of 2025
OPERA-02: enrollment ongoing, November 2026
Partnership: Novartis clinical collaboration for ribociclib and alpelisib combinations (2020, amended 2022 and 2023)
Partnership: Novartis ribociclib supply for OPERA-02 (2024)
Partnership: Pfizer palbociclib (2020) and atirmociclib (2025) agreements
Patents: composition of matter to 2036; pending applications to 2040 to 2046
Regulatory status outside the United States
No evidence found.